Recently, p73, a protein with structural and functional similarities to p53
, an extensively studied tumor suppressor gene, has been cloned. After bein
g mapped to the chromosomal region 1p35-1p36, it has been postulated to act
as a tumor suppressor gene, too, as this region is altered in several huma
n malignancies. Deletions of the short arm of chromosome 1 have frequently
been described in multiple myeloma (MM) whereas structural abnormalities of
the 17p13 region including p53 are rare events in this disease. Since it h
as been proposed that especially neoplasias lacking p53 alterations might s
how a loss of heterozygosity at 1p35-1p36, we studied the frequency of p53
and p73 deletions in bone marrow mononuclear cells of 68 patients with MM,
two patients with monoclonal gammopathy of undetermined significance and fo
ur patients with plasma cell leukemia. Dual-color fluorescence in situ hybr
idization (FISH) for p53 and p73 was performed using commercially available
DNA probes for 17p13.3 and the microsatellite marker D1Z2, respectively. C
entromeric DNA probes served to distinguish gene deletions from whole chrom
osome losses. In contrast to recently published FISH results, we only detec
ted heterozygous p53 deletions in eight out of the 74 patients, three of th
em showing a monosomy 17. Heterozygous deletions of the D1Z2 region at 1p36
were found in six cases with one patient having a monosomy 1. Neither homo
zygous deletions of either chromosomal region nor nullisomies 1 or 17 could
be detected. These results argue against a major role of p73 deletions in
MM. As MM patients with Ip structural abnormalities have a significantly po
orer survival rate than those with normal karyotypes, the role of other put
ative tumor suppressor genes located at the chromosomal region 1p36 in the
pathogenesis of MM has to be determined.